Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod ; volume:271 ; number:10 ; day:23 ; month:8 ; year:2024 ; pages:6773-6781 ; date:10.2024
Journal of neurology ; 271, Heft 10 (23.8.2024), 6773-6781, 10.2024
- Urheber
-
Carotenuto, Antonio
Di Monaco, Cristina
Papetti, Laura
Borriello, Giovanna
Signoriello, Elisabetta
Masciulli, Camilla
Tomassini, Valentina
De Luca, Giovanna
Ianniello, Antonio
Lus, Giacomo
Novarella, Federica
Spiezia, Antonio Luca
Di Somma, Dario
Moccia, Marcello
Petracca, Maria
Iacovazzo, Carmine
Servillo, Giuseppe
Portaccio, Emilio
Triassi, Maria
Amato, Maria Pia
Pozzilli, Carlo
Valeriani, Massimiliano
Brescia Morra, Vincenzo
Lanzillo, Roberta
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-024-12610-y
- URN
-
urn:nbn:de:101:1-2412192205015.457470867188
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Carotenuto, Antonio
- Di Monaco, Cristina
- Papetti, Laura
- Borriello, Giovanna
- Signoriello, Elisabetta
- Masciulli, Camilla
- Tomassini, Valentina
- De Luca, Giovanna
- Ianniello, Antonio
- Lus, Giacomo
- Novarella, Federica
- Spiezia, Antonio Luca
- Di Somma, Dario
- Moccia, Marcello
- Petracca, Maria
- Iacovazzo, Carmine
- Servillo, Giuseppe
- Portaccio, Emilio
- Triassi, Maria
- Amato, Maria Pia
- Pozzilli, Carlo
- Valeriani, Massimiliano
- Brescia Morra, Vincenzo
- Lanzillo, Roberta
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod Therapy for Multiple Sclerosis
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod Therapy for Multiple Sclerosis
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod Therapy for Multiple Sclerosis
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Natalizumab May Improve Cognition and Mood in Multiple Sclerosis
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis